论文部分内容阅读
Lepri 等利用[~(125)Ⅰ]5-碘脱氧尿嘧啶(~(125)IUdR)参入小鼠和病人白血病细胞DNA,以检测抗癌药的体外抗增殖活性。将白血病细胞与抗癌药共同孵育1h,药物浓度应等于鼠或病人在每天给药后体液中的浓度。去除药物后48h,培养细胞中加入~(125)IUdR 和FUdR,18h 后收集细胞检测DNA 合成。结果表明,同位素参入DNA 的抑制率超过50%与体内抗小鼠白血病(L1210,P388和耐阿霉素的P388)药物活性相关。对急性白血病的初步数据提示,该法适用于选择最有效的体内治疗方案。
Lepri and other [125I] 5-iododeoxyuridine (~ (125) IUdR) into the mouse and patient leukemia cell DNA, in order to test anti-cancer drug anti-proliferative activity in vitro. Incubation of leukemia cells with anti-cancer drugs for 1 h, the drug concentration should be equal to the concentration of the murine or patient in the body fluid after daily administration. Forty-eight hours after the drug was removed, ~ (125) IUdR and FUdR were added to the cultured cells, and the cells were collected 18 hours later to detect the DNA synthesis. The results showed that isotope incorporation of DNA in more than 50% inhibition rate was associated with the in vivo anti-mouse leukemia (L1210, P388 and doxorubicin-resistant P388) drug activity. Preliminary data on acute leukemias suggest that this method is suitable for selecting the most effective in vivo treatment regimen.